Preparing an oncolytic poliovirus recombinant for clinical application against glioblastoma multiforme [0.03%]
疱疹病毒重组体的临床应用制备用于治疗多形性胶质母细胞瘤
Christian Goetz,Matthias Gromeier
Christian Goetz
PVS-RIPO is a genetically recombinant, non-pathogenic poliovirus chimera with a tumor-specific conditional replication phenotype. Consisting of the genome of the live attenuated poliovirus type 1 (Sabin) vaccine with its cognate IRES elemen...
Fabrice Le Boeuf,John C Bell
Fabrice Le Boeuf
There is an urgent need for innovative therapeutic strategies to treat aggressive metastatic cancers that are incurable with standard therapeutic approaches. Novel treatment strategies like oncolytic virotherapy have led, in some cases, to ...
Directing systemic oncolytic viral delivery to tumors via carrier cells [0.03%]
通过载体细胞直接将系统性溶瘤病毒递送至肿瘤中
Hiroshi Nakashima,Balveen Kaur,E A Chiocca
Hiroshi Nakashima
The systemic administration of oncolytic virus (OV) is often inefficient due to clearance of the virus by host defense mechanism and spurious targeting of non-cancer tissues through the bloodstream. Cell mediated OV delivery could hide the ...
Byram W Bridle,Stephen Hanson,Brian D Lichty
Byram W Bridle
The interactions between the immune system, a malignant tumour and an oncolytic virus are complex and poorly understood. For oncolytic viruses to become successful therapeutics we need to better understand these interactions and identify st...
Clinical trials with oncolytic reovirus: moving beyond phase I into combinations with standard therapeutics [0.03%]
肿瘤溶瘤病毒的临床试验：从一期走向与标准疗法联合治疗
K J Harrington,R G Vile,A Melcher et al.
K J Harrington et al.
It is time for those working on oncolytic viruses to take stock of the status of the field. We now have at our disposal an array of potential therapeutic agents, and are beginning to conduct early-phase clinical trials in patients with rela...
Marianne M Stanford,John C Bell,Markus J V Vähä-Koskela
Marianne M Stanford
The use of viruses as targeted cancer therapy has shown significant promise, and the list of oncolytic viruses continue to grow. The interest in unexplored viruses as oncolytic agents is a natural corollary to the successes and challenges o...
Jean Rommelaere,Karsten Geletneky,Assia L Angelova et al.
Jean Rommelaere et al.
The experimental infectivity and excellent tolerance of some rodent autonomous parvoviruses in humans, together with their oncosuppressive effects in preclinical models, speak for the inclusion of these agents in the arsenal of oncolytic vi...
Oncolytic viral purging of leukemic hematopoietic stem and progenitor cells with Myxoma virus [0.03%]
瘤苗病毒清除白血病造血干细胞和祖细胞的研究——以痘苗病毒为例
Masmudur M Rahman,Gerard J Madlambayan,Christopher R Cogle et al.
Masmudur M Rahman et al.
High-dose chemotherapy and radiation followed by autologous blood and marrow transplantation (ABMT) has been used for the treatment of certain cancers that are refractory to standard therapeutic regimes. However, a major challenge with ABMT...
A call to arms: using RNAi screening to improve oncolytic viral therapy [0.03%]
迫切呼吁：利用RNA干扰筛选技术改善溶瘤病毒疗法
D J Mahoney,D F Stojdl
D J Mahoney
Replicating virus-based therapeutics for cancer, or oncolytic virus therapy (OVT), is rapidly emerging as a promising treatment modality for a wide range of cancers. In pre-clinical studies, oncolytic viruses have produced remarkable result...
Molecular mechanisms of perineural invasion, a forgotten pathway of dissemination and metastasis [0.03%]
外周神经侵犯的分子机制：一条被遗忘的转移通路
Federica Marchesi,Lorenzo Piemonti,Alberto Mantovani et al.
Federica Marchesi et al.
Invasion and metastasis are key components of cancer progression. Inflammatory mediators, including cytokines and chemokines, can facilitate tumor dissemination. A distinct and largely forgotten path is perineural invasion (PNI), defined as...